Live Breaking News & Updates on Johnson innovative medicines

Stay updated with breaking news from Johnson innovative medicines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Quanterix Corporation (NASDAQ:QTRX) Q3 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Quanterix Corporation Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode. ....

Amsterdam , Noord-holland , Netherlands , Ted-joyce , Masoud-toloue , Vandana-sriram , Eli-lilly , Mike-doyle , Alzheimer-association , A-research-scientist , Quanterix-corporation , Quanterix-corp

Guselkumab for the Treatment of Crohn Disease, with Remo Panaccione, MD

In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice. ....

Remo-panaccione , University-of-calgary , Johnson , Drug-administration , Johnson-innovative-medicines , United-european-gastroenterology-week , Inflammatory-bowel-disease-unit , Severely-active-crohn , Participants-with-moderately , Demonstrates-long-term-benefit , Crohn-disease , Cd

Guselkumab Demonstrates Long-Term Benefit for Crohn Disease

During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response. ....

Jan-wehkamp , Anita-afzali , Uc-health-anita-afzali , Johnson , University-of-cincinnati-college-medicine , Johnson-innovative-medicines , United-european-gastroenterology-week , Cincinnati-college , Johnson-innovative , Severely-active-crohn , Participants-with-moderately , Achieved-clinical-remission